dc.contributor.author | ATILGAN, D | |
dc.contributor.author | KOYLAN, N | |
dc.contributor.author | GOREN, T | |
dc.contributor.author | EREN, N | |
dc.contributor.author | CUBUKCU, A | |
dc.contributor.author | MERIC, M | |
dc.date.accessioned | 2021-03-03T11:36:38Z | |
dc.date.available | 2021-03-03T11:36:38Z | |
dc.identifier.citation | MERIC M., GOREN T., ATILGAN D., EREN N., CUBUKCU A., KOYLAN N., "METABOLIC, HEMATOLOGICAL, AND CARDIAC EFFECTS OF LONG-TERM ISRADIPINE TREATMENT IN MILD-TO-MODERATE ESSENTIAL-HYPERTENSION", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, cilt.19, 1992 | |
dc.identifier.issn | 0160-2446 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_28dc5216-3d61-48ca-ab28-abf4a98c6b62 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/32317 | |
dc.description.abstract | Twenty-four patients with mild-to-moderate hypertension (19 women, 5 men; mean age of 49 +/- 9.1 years) completed a 2-week washout phase followed by 1 week of single-blind placebo. Patients were then given isradipine at 2.5 mg twice daily, which was increased to up to 7.5 mg twice daily according to the blood pressure response, over a 12-month period. Thirteen patients completed the trial. The supine and sitting blood pressure decreased to normal levels within 6 weeks of starting active treatment. Heart rate remained unchanged. Plasma cholesterol and triglycerides did not change significantly. Plasma high-density lipoprotein (HDL) cholesterol increased significantly (p < 0.05) and a decrease (NS) was observed in low-density lipoprotein (LDL) cholesterol and in the LDL/HDL cholesterol ratio. Very-low-density lipoprotein (VLDL) cholesterol did not change, nor did other biochemical laboratory tests, or electrocardiographic and echocardiographic parameters. The most notable side effects were headache (n = 1), flushing (n = 1), palpitations (n = 3), and pretibial edema (n = 1). In conclusion, our results indicate that isradipine is safe and effective in the long-term treatment of mild-to-moderate hypertension. It also appears to have beneficial effects on lipid metabolism. | |
dc.language.iso | eng | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Kardiyoloji | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | CARDIAC ve CARDIOVASCULAR SİSTEMLER | |
dc.title | METABOLIC, HEMATOLOGICAL, AND CARDIAC EFFECTS OF LONG-TERM ISRADIPINE TREATMENT IN MILD-TO-MODERATE ESSENTIAL-HYPERTENSION | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | |
dc.contributor.department | , , | |
dc.identifier.volume | 19 | |
dc.contributor.firstauthorID | 113191 | |